Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease

Ann Marie Schmidt1

  • 1Diabetes Research Program, Division of Endocrinology, Department of Medicine, New York University Langone Medical Center, 550 First Avenue, New York, NY 10016, United States.

Insights

Soluble forms of the receptor for advanced glycation endproducts (RAGE) are linked to chronic diseases. These soluble RAGEs may serve as biomarkers for disease activity in metabolic and inflammatory conditions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • The receptor for advanced glycation endproducts (RAGE) is implicated in tissue damage in chronic metabolic and inflammatory diseases.
  • Circulating levels of soluble RAGEs in human plasma/serum are reported as potential biomarkers.

Purpose of the Study:

  • To review the current understanding of soluble RAGEs.
  • To explore their formation, natural functions, and potential as biomarkers for disease activity.
  • To identify areas for future scientific investigation.

Main Methods:

  • Literature review of existing evidence on RAGE and soluble RAGEs.
  • Analysis of reports on RAGE in human subjects and disease pathogenesis.

Main Results:

  • Emerging evidence connects RAGE to the pathogenesis of tissue damage in chronic diseases.
  • Soluble RAGE forms in circulation may indicate the presence and extent of chronic disease.

Conclusions:

  • Soluble RAGEs are potential biomarkers for inflammatory and metabolic disease activity.
  • Further research is needed to fully elucidate the biology of soluble RAGEs and their clinical utility.
Keywords:
Soluble RAGE

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.8K
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
5.2K
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.9K